The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
N1-(2-aminophenyl)-N8-(4-(1-benzyl-1H-1,2,3-triazol-4-yl)phenyl)octanediamide ID: ALA4293438
PubChem CID: 145988785
Max Phase: Preclinical
Molecular Formula: C29H32N6O2
Molecular Weight: 496.62
Molecule Type: Small molecule
Associated Items:
Names and Identifiers Canonical SMILES: Nc1ccccc1NC(=O)CCCCCCC(=O)Nc1ccc(-c2cn(Cc3ccccc3)nn2)cc1
Standard InChI: InChI=1S/C29H32N6O2/c30-25-12-8-9-13-26(25)32-29(37)15-7-2-1-6-14-28(36)31-24-18-16-23(17-19-24)27-21-35(34-33-27)20-22-10-4-3-5-11-22/h3-5,8-13,16-19,21H,1-2,6-7,14-15,20,30H2,(H,31,36)(H,32,37)
Standard InChI Key: IYKIQDXPWYJSPM-UHFFFAOYSA-N
Molfile:
RDKit 2D
37 40 0 0 0 0 0 0 0 0999 V2000
16.9837 -12.4810 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9878 -13.3023 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
17.6934 -12.0647 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.6892 -11.2434 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.4006 -10.8333 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.3968 -10.0128 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.6823 -9.6029 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9703 -10.0236 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9776 -10.8428 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.1138 -11.2397 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.2739 -12.0719 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.5641 -12.4882 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.8502 -12.0791 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1405 -12.4954 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4266 -12.0863 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4224 -11.2650 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7085 -10.8600 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.7043 -10.0387 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
11.9988 -11.2722 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
13.4141 -9.6224 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1257 -10.0340 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.8350 -9.6184 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.8312 -8.7962 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
14.1123 -8.3914 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.4060 -8.8053 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.5393 -8.3818 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.2920 -8.7093 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.8349 -8.0944 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
16.4218 -7.3852 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
15.6195 -7.5644 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.7493 -6.6324 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.5656 -6.5416 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.0527 -7.2063 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.8682 -7.1160 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.1965 -6.3626 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.7073 -5.6986 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
17.8934 -5.7922 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
1 3 1 0
3 4 1 0
4 5 2 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
9 4 1 0
5 10 1 0
1 11 1 0
11 12 1 0
12 13 1 0
13 14 1 0
14 15 1 0
15 16 1 0
16 17 1 0
17 18 1 0
17 19 2 0
18 20 1 0
20 21 2 0
21 22 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 20 1 0
26 27 1 0
27 28 2 0
28 29 1 0
29 30 1 0
30 26 2 0
23 26 1 0
29 31 1 0
31 32 1 0
32 33 2 0
33 34 1 0
34 35 2 0
35 36 1 0
36 37 2 0
37 32 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 496.62Molecular Weight (Monoisotopic): 496.2587AlogP: 5.49#Rotatable Bonds: 12Polar Surface Area: 114.93Molecular Species: NEUTRALHBA: 6HBD: 3#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 4#RO5 Violations (Lipinski): 1CX Acidic pKa: 13.56CX Basic pKa: 3.45CX LogP: 5.22CX LogD: 5.22Aromatic Rings: 4Heavy Atoms: 37QED Weighted: 0.18Np Likeness Score: -1.31
References 1. Adhikari N, Amin SA, Trivedi P, Jha T, Ghosh B.. (2018) HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches., 157 [PMID:30179749 ] [10.1016/j.ejmech.2018.08.081 ] 2. Sangwan R, Rajan R, Mandal PK.. (2018) HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors., 158 [PMID:30245394 ] [10.1016/j.ejmech.2018.08.073 ] 3. Sarkar R, Banerjee S, Amin SA, Adhikari N, Jha T.. (2020) Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review., 192 [PMID:32163814 ] [10.1016/j.ejmech.2020.112171 ]